Geron (NASDAQ:GERN) Announces Earnings Results, Beats Estimates By $0.05 EPS

Geron (NASDAQ:GERN) released its earnings results on Thursday. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.05, Briefing.com reports. Geron had a negative net margin of 15,990.68% and a negative return on equity of 73.79%. The business had revenue of $28.27 million for the quarter, compared to analyst estimates of $18.97 million. During the same quarter in the previous year, the business earned ($0.08) earnings per share. Geron’s revenue for the quarter was up 17138.4% on a year-over-year basis.

Geron Price Performance

Shares of NASDAQ GERN opened at $4.25 on Friday. The stock has a market cap of $2.56 billion, a price-to-earnings ratio of -11.81 and a beta of 0.52. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.60 and a current ratio of 3.61. Geron has a fifty-two week low of $1.64 and a fifty-two week high of $5.34. The firm’s 50-day simple moving average is $4.31 and its 200 day simple moving average is $4.31.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. HC Wainwright started coverage on Geron in a research note on Tuesday, November 5th. They issued a “buy” rating and a $8.00 price objective on the stock. Needham & Company LLC reissued a “buy” rating and issued a $6.00 price target on shares of Geron in a research note on Friday, August 9th. Leerink Partners initiated coverage on shares of Geron in a research report on Monday, September 9th. They set an “outperform” rating and a $7.00 price objective for the company. Wedbush reiterated an “outperform” rating and issued a $8.00 price objective on shares of Geron in a research note on Thursday, August 8th. Finally, Scotiabank started coverage on shares of Geron in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Geron presently has an average rating of “Moderate Buy” and a consensus target price of $7.05.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.